Research
Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy
Cancer Medicine – March 01, 2025
Summary
Psychedelics, like psilocybin, offer a compelling new medicine for the profound undertreatment of cancer pain and associated psychological distress. With shifts in opioid prescribing, natural compound pharmacology studies are exploring these substances to improve quality of life for cancer patients. Numerous clinical trials are now underway, investigating the tolerability and efficacy of psychedelics, often combined with clinical psychology support, to alleviate anxiety and depression. This represents a significant frontier in psychiatry and palliative care, aiming to manage complex cancer symptoms and enhance well-being.
Abstract
ABSTRACT Purpose To evaluate the current level of evidence for the use of psychedelics for the management of cancer pain and associated psychologic...
Tinnitus, lucid dreaming and awakening. An online survey and theoretical implications.
Hearing research – March 01, 2025
Summary
No Summary
Abstract
Tinnitus is the perception of phantom sound in the absence of a corresponding external source. Previous studies reported that the presence of tinni...
Long-term ayahuasca use is associated with preserved global cognitive function and improved memory: a cross-sectional study with ritual users.
European archives of psychiatry and clinical neuroscience – March 01, 2025
Summary
Regular users of ayahuasca, a traditional Amazonian brew made from Banisteriopsis caapi and Psychotria viridis plants, show enhanced memory performance compared to newer users. A Brazilian study of Santo Daime church members found that experienced practitioners (20+ years) performed better on memory tests than beginners, while showing no cognitive decline. Long-term use appears to boost both verbal and visual memory.
Abstract
Although several studies have been conducted to elucidate the relationship between psychedelic consumption and cognition, few have focused on under...
Can We Better Understand, Diagnose, and Treat Ketamine-Induced Uropathy, and Can It Be Reversed? ICI-RS 2024.
Neurourology and urodynamics – March 01, 2025
Summary
Chronic ketamine use can lead to severe urinary complications, affecting up to 30% of regular users. Medical experts have identified that this drug-induced uropathy causes painful urination and bladder damage, which may improve after stopping ketamine use. Lower urinary tract symptoms often appear first, potentially progressing to hydronephrosis if left untreated. Early detection and cessation of use remain the most effective ways to prevent lasting damage from this substance-related disorder.
Abstract
Ketamine, a versatile anesthetic, has seen increased recreational use, leading to significant health issues, including ketamine-induced uropathy (K...
Ketamine Use for Palliative Care in the Austere Environment: Is Ketamine the Path Forward for Palliative Care.
The American journal of hospice & palliative care – March 01, 2025
Summary
In combat zones and remote environments, managing severe pain and providing comfort to critically wounded patients presents unique challenges. Ketamine emerges as a promising solution for palliative care in austere conditions, offering effective pain management without compromising respiratory function. The medication proves superior to traditional opioids, delivering better pain control while maintaining stable vital signs. Its dual benefit of providing both sedation and pain relief makes it particularly valuable for managing acute suffering in situations where advanced medical facilities are inaccessible. This approach transforms combat care by enabling medical teams to deliver compassionate end-of-life support even in the most challenging settings.
Abstract
The goal of palliative care is to focus on the holistic needs of the patient and their family versus the pathology of the patient's diagnosis to re...
Unpacking the complexities of consciousness: Theories and reflections.
Neuroscience and biobehavioral reviews – March 01, 2025
Summary
No Summary
Abstract
As the field of consciousness science matures, the research agenda has expanded from an initial focus on the neural correlates of consciousness, to...
Anhedonia: Current and future treatments
Psychiatry and Clinical Neurosciences Reports – March 01, 2025
Summary
Traditional antidepressants often struggle against anhedonia, the inability to feel pleasure, which significantly impedes recovery from conditions like Major Depression. However, a diverse range of treatments offers hope. Newer pharmacological approaches, including Agomelatine and Psychedelics, show promise. Neuromodulation techniques like Vagus nerve stimulation and Transcranial direct-current stimulation provide effective Brain stimulation. Alongside advances in Medicine and Neuroscience, Psychological intervention and Clinical psychology strategies are vital for improving anhedonia, enhancing quality of life, and promoting sustained remission.
Abstract
Abstract Anhedonia is a transdiagnostic domain that leads to poor disorder outcome and low remission rates. This narrative review describes a broad...
Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy.
Wiener klinische Wochenschrift – March 01, 2025
Summary
When traditional antidepressant treatments fail, new hope emerges: nasal esketamine and modern electroconvulsive therapy (ECT) show remarkable success in treating stubborn depression. Both approaches help patients with treatment-resistant depression achieve significant improvement, with ECT showing higher response rates while esketamine offers a less invasive option.
Abstract
Modern electroconvulsive therapy (ECT) and the approval of nasal esketamine for clinical use have significantly improved the approach to treatment-...
The Restoration of Energy Pathways Indicates the Efficacy of Ketamine Treatment in Depression: A Metabolomic Analysis.
CNS neuroscience & therapeutics – March 01, 2025
Summary
Breakthrough research reveals how ketamine fights depression by restoring vital energy pathways in the brain. Scientists tracked metabolic changes in patients with major depressive disorder, finding that those who responded well to ketamine showed significant improvements in energy-related molecules. The study found that baseline thyroxine levels could predict treatment success, offering a potential way to identify patients most likely to benefit.
Abstract
Despite the clinical benefits of ketamine in treating major depressive disorder (MDD), some patients exhibit drug resistance, and the intricate mec...
(2R, 6R)-hydroxynorketamine alleviates postictal depression induced by pilocarpine through modulating LRP4 expression in hippocampal astrocytes.
Epilepsy & behavior : E&B – March 01, 2025
Summary
A promising ketamine derivative shows potential in treating depression that follows epileptic seizures. Scientists found that (2R, 6R)-hydroxynorketamine reduces depression symptoms by regulating a key protein (LRP4) in brain cells. The treatment works quickly and lasts for days, without the side effects associated with ketamine, offering hope for better management of post-seizure depression.
Abstract
Postictal depression is a common comorbidity in epilepsy, yet effective treatments remain limited. While ketamine is well-known for its antidepress...
Effect of continuous esketamine infusion on brain white matter microstructure in patients with major depression: A diffusion tensor imaging study.
Journal of affective disorders – March 01, 2025
Summary
A groundbreaking antidepressant treatment, esketamine, shows rapid mood improvement in patients with major depressive disorder, despite not immediately repairing brain tissue connectivity. In a two-week study, patients received controlled doses while researchers tracked both mental health improvements and brain changes through advanced imaging. Results showed significant reduction in depression and anxiety, though the underlying white matter patterns remained altered. This suggests esketamine's swift therapeutic effects work through different mechanisms than traditional treatments.
Abstract
Esketamine has demonstrated acute antidepressant effects in patients with major depressive disorder (MDD). This study investigated whether these ef...
Ecstasy, molly, MDMA: What health practitioners need to know about this common recreational drug.
Disease-a-month : DM – March 01, 2025
Summary
MDMA, known as ecstasy or molly, affects both mind and body by releasing mood-enhancing chemicals. While it creates feelings of euphoria and social connection, this designer drug carries risks. Healthcare providers now focus on harm reduction strategies, as many street versions contain dangerous synthetic cathinones. Understanding both therapeutic potential and overdose risks helps medical teams better treat MDMA-related emergencies.
Abstract
3,4-methylenedioxymethamphetamine (MDMA; commonly referred to as "ecstasy" or "molly") is a substituted amphetamine drug that is used recreationall...
The effects of Rajyoga mindfulness meditation training on heart rate variability in panic disorder: A randomized controlled trial.
Indian journal of psychiatry – March 01, 2025
Summary
No Summary
Abstract
Panic disorder is associated with autonomic nervous system dysfunction and reduced heart rate variability (HRV). Enhancing HRV may help mitigate sy...
Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials.
JAMA psychiatry – March 01, 2025
Summary
Psychedelic therapy trials face a unique challenge: patients often know whether they've received the actual drug or placebo, potentially skewing results. Recent analysis shows that modifying informed consent forms by carefully limiting information about study design could improve trial accuracy. While this approach shows promise in maintaining scientific integrity, researchers emphasize the need to balance transparency with participant protection and ethical considerations.
Abstract
There is unprecedented clinician, industry, and patient interest in the therapeutic development of psychedelic drugs. This is due to a combination ...
Esketamine-mediated alleviation of electroconvulsive shock-induced memory impairment is associated with the regulation of mGluR5 in depressive-like rats.
Pharmacology, biochemistry, and behavior – March 01, 2025
Summary
A breakthrough in depression treatment shows how esketamine can protect memory during electroconvulsive therapy. By activating specific brain receptors, including metabotropic glutamate receptors, this medication helps preserve learning and memory functions. Lab tests revealed that rats receiving esketamine maintained better cognitive abilities and showed fewer depression symptoms after treatment.
Abstract
Electroconvulsive therapy (ECT) is recognized as one of the most efficacious interventions for depression. However, it is associated with impairmen...
Differences in the clinical presentation of acute 3,4-methylenedioxymetamfetamine intoxication by co-intoxication and patient sex to European emergency departments.
Clinical toxicology (Philadelphia, Pa.) – March 01, 2025
Summary
MDMA (also known as ecstasy) affects men and women differently in emergency situations, according to data from European hospitals. When combined with alcohol or other drugs, MDMA intoxication shows distinct patterns. While alcohol mixture increases agitation and vomiting, combining MDMA with other substances can lead to more severe symptoms like psychosis. Women experience more vomiting and headaches, while men report more chest pain. Despite these risks, mortality remains low.
Abstract
This study hypothesized that 3,4-methylenedioxymetamfetamine intoxication presents with distinct clinical features and outcomes when combined with ...
Pharmacological characterization of cannabidiol as a negative allosteric modulator of the 5-HT2A receptor.
Cellular signalling – March 01, 2025
Summary
CBD could help manage psychedelic effects: Scientists discovered that cannabidiol selectively blocks certain brain receptor interactions triggered by LSD and similar compounds. This finding explains how CBD might reduce hallucinations while preserving potential therapeutic benefits of psychedelic treatments, offering a promising path for safer mental health therapies.
Abstract
Promising clinical evidence suggests that psychedelic compounds, like lysergic acid diethylamide (LSD), have therapeutic value for treatment of psy...
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.
Journal of affective disorders – March 01, 2025
Summary
Higher doses of psilocybin create more profound psychedelic experiences, which strongly correlate with better outcomes in people with treatment-resistant depression. A single dose, combined with psychological support, showed that participants who reported deeper mystical experiences and visual effects were more likely to see significant improvements in their depression symptoms after three weeks.
Abstract
To determine the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcome in treatment-resistant depression. For tre...
Efficient and modular synthesis of ibogaine and related alkaloids.
Nature chemistry – March 01, 2025
Summary
Ibogaine, a natural compound, shows promise for treating addiction. Researchers developed an efficient, gram-scale method to create ibogaine and similar compounds from common materials. This new approach allowed for the creation of several related alkaloids and new variations. Notably, one new compound, (-)-10-fluoroibogamine, demonstrated exceptional brain-healing properties and strongly modulated serotonin, a key brain chemical. This breakthrough provides a powerful way to produce these important compounds for exploring their therapeutic potential.
Abstract
Anecdotal reports and preliminary clinical trials suggest that the psychoactive alkaloid ibogaine and its active metabolite noribogaine have powerf...
Low-dose ketamine improved brain network integrity among patients with treatment-resistant depression and suicidal ideation.
Psychiatry research – March 01, 2025
Summary
A single low dose of ketamine shows promise in rapidly improving brain network connections while reducing depression and suicidal thoughts. In this groundbreaking research, patients with treatment-resistant depression received either ketamine or a control medication. Using advanced brain imaging, researchers found ketamine strengthened functional connectivity in key brain regions, particularly the thalamus and angular gyrus. These improvements in brain network organization corresponded with significant reductions in depressive symptoms and suicidal ideation.
Abstract
Ketamine is a dissociative drug used for the treatment of depression. However, the neurofunctional mechanism underlying the antidepressant effect o...
The Impact of Ketamine-Based Versus Non-Ketamine-Based ECT Anesthesia Regimens on the Severity of Patients' Depression and Occurrence of Adverse Events: A Systematic Review with Meta-Analysis.
The Annals of pharmacotherapy – March 01, 2025
Summary
Ketamine, a powerful NMDA antagonist, may boost the effectiveness of electroconvulsive therapy (ECT) in treating severe depression. Analysis of 17 clinical trials revealed that patients receiving ketamine anesthesia during ECT were 78% more likely to achieve remission from treatment-resistant depression compared to those given standard anesthesia. While this combination showed faster improvement in depression scores, patients experienced more temporary side effects like hallucinations.
Abstract
To compare efficacy and safety outcomes for ketamine anesthesia + electroconvulsive therapy (ECT) versus nonketamine anesthesia + ECT in treatment-...
The Hallucinogen Rating Scale: Updated Factor Structure in a Large, Multistudy Sample.
Biological psychiatry global open science – March 01, 2025
Summary
Psychedelics like psilocybin and DMT create distinct patterns of consciousness that can now be reliably measured. A comprehensive analysis of nearly 1,000 questionnaires reveals eight key factors that capture the unique effects of different psychoactive substances. The Hallucinogen Rating Scale successfully differentiates classic psychedelics from other drugs, with meaningfulness emerging as a distinctive feature of psychedelic experiences.
Abstract
The Hallucinogen Rating Scale (HRS) has been widely used to measure the subjective effects of psychedelics and other psychoactive substances. Its a...
Assessment of laparotomy-induced stress response in opium- and morphine-addicted rats by measuring serum glucose and corticosterone levels: an animal experiment.
Annals of medicine and surgery (2012) – March 01, 2025
Summary
Regular opium and morphine use may alter how the body responds to surgery. In an animal study, rats addicted to these substances showed significantly lower stress responses during laparotomy compared to non-addicted rats. Blood tests revealed reduced glucose and stress hormone levels in addicted rats after surgery, suggesting chronic opioid use dampens the body's natural surgical stress response.
Abstract
Surgical procedures induce stress responses similar to severe illnesses, activating the metabolic and neuroendocrine systems, especially the hypoth...
Molecular insights into the modulation of the 5HT2A receptor by serotonin, psilocin, and the G protein subunit Gqα.
FEBS letters – March 01, 2025
Summary
Breakthrough research reveals how psychedelics like psilocin interact with brain receptors at the molecular level. Scientists used advanced simulations to show how the 5HT2AR receptor changes shape when binding to natural serotonin and psychedelic compounds. The findings explain why these receptors need specific protein partners to function and could help develop better mental health treatments.
Abstract
5HT2AR is a G-protein-coupled receptor that drives many neuronal functions and is a target for psychedelic drugs. Understanding ligand interactions...
Trial Sequential Analysis and Meta-analysis of Intranasal Ketamine Versus Intranasal Opioids for Analgesia in Paediatric Patients.
Annals of neurosciences – March 01, 2025
Summary
Intranasal ketamine offers a needle-free option for pain relief in children, rivaling traditional opioid medications. Analysis of data from nearly 500 pediatric patients showed comparable pain control between ketamine and opioids when delivered through the nose. While both treatments effectively reduced pain, ketamine users experienced more side effects like dizziness. This research helps doctors better understand medication choices for young patients needing analgesia.
Abstract
Ketamine (KT) is known to have analgesic and sedative effects. Intranasal (IN)/inhalational KT has been used in different trials involving paediatr...
Interest and limits of using pharmacogenetics in MDMA-related fatalities: A case report.
Forensic science international. Genetics – March 01, 2025
Summary
Genetic variations can significantly impact how individuals process MDMA (3,4-Methylenedioxymethamphetamine), as revealed in a forensic investigation. Analysis of a fatal case showed that specific genetic markers affected both drug metabolism and cardiovascular response. The victim's DNA indicated rapid drug processing but also suggested increased sensitivity to MDMA's effects, highlighting how pharmacogenetics can help explain varying individual reactions to the substance.
Abstract
Interpreting postmortem concentrations of 3,4-Methylenedioxymethamphetamine (MDMA) remains challenging due to the wide range of reported results an...
The Selective 5HT2A Receptor Agonist, 25CN-NBOH Exerts Excitatory and Inhibitory Cellular Actions on Mouse Medial Prefrontal Cortical Neurons.
Synapse (New York, N.Y.) – March 01, 2025
Summary
No Summary
Abstract
Psychedelic compounds have gained renewed interest due to their rapid and long-lasting therapeutic effects on stress-related disorders. While the u...
Dimethyltryptamine (DMT) and ibogaine elicit membrane effects in HEK cells transiently transfected with the human 5-HT2A receptor.
Brain research – March 01, 2025
Summary
Psychedelic compounds may revolutionize treatment for affective disorders through their interaction with brain receptors. Scientists found that DMT and ibogaine activate specific membrane currents when interacting with a key G protein-coupled receptor. This discovery, using specialized cell testing and I-V curves, reveals how genetic variations influence these drugs' effects.
Abstract
Psychedelics show promise in treating psychiatric disorders. Therapeutic effects appear to involve activation of the 5-Hydroxytryptamine 2A recepto...
Anesthetic effects of a mixture of xylazine, ketamine, and buprenorphine in laboratory rats subjected to short surgical procedures.
Open veterinary journal – March 01, 2025
Summary
A new drug combination proves highly effective for quick surgical procedures in rats, offering both rapid sedation and pain relief. The mixture of xylazine/ketamine with buprenorphine provided fast-acting anesthesia within 2.3 minutes, while atipamezole ensured swift recovery. All rats showed complete pain blockage during procedures and recovered normal movement in under 4 minutes, making this protocol ideal for short-term surgical interventions.
Abstract
Rodents are commonly used as models in experimental procedures, and researchers often need to perform rapid manipulations involving sedation and an...
Do undergraduates’ views of psychedelics relate to the context for psychedelic use?
Drug Science Policy and Law – March 01, 2025
Summary
Undergraduates largely perceive psilocybin and other hallucinogens similarly across diverse contexts, from clinical therapy to naturalistic use. A study of 277 psychedelic-naïve undergraduates (75.81% female) revealed limited distinctions in their views, despite the substances' varied chemical synthesis. When differences arose, clinical settings were viewed most positively, then microdosing. Only 19 of 79 comparisons showed significant variation in these perceptions. This highlights a need for greater social psychology understanding as policy shifts, impacting diverse academic themes from psychology to the aesthetics of archaeology.
Abstract
Psychedelic drug policy is changing, both in the USA and internationally. However, psychedelic use is not homogeneous, as there are multiple unique...
Acute complications and treatment in critically ill patients with 3,4-methylenedioxymetamfetamine intoxication: a 10-year retrospective observational study in an intensive care unit in an Amsterdam hospital.
Clinical toxicology (Philadelphia, Pa.) – March 01, 2025
Summary
MDMA (ecstasy) emergencies reveal surprising dangers: jaw-locking (trismus) was the top reason for intensive care admission in Amsterdam, affecting nearly half of cases. Over 10 years, doctors tracked 74 patients with severe reactions. Beyond locked jaws causing breathing problems, dangerous sodium imbalances and high body temperatures posed serious risks. While most patients recovered, complications were severe in those with hyperthermia above 39°C.
Abstract
The persistent increase in the use of 3,4-methylenedioxymetamfetamine has led to an increase in emergency department presentations. Our aim was to ...
Effects of Chronic Social Isolation Stress and Alcohol on the Reinforcing Properties of Ketamine in Male and Female Rats.
eNeuro – March 01, 2025
Summary
Social isolation and alcohol use can significantly alter how ketamine affects the brain, with notable differences between males and females. Research reveals that female subjects consumed more ketamine than males, while prior alcohol exposure increased ketamine intake specifically in females. In males, both isolation and alcohol independently led to higher ketamine use. These behavioral changes were matched by physical alterations in brain cell connections (spines) within the nucleus accumbens, a key reward center. The findings highlight important sex-specific interactions between stress, alcohol, and ketamine response.
Abstract
While ketamine, an NMDA receptor antagonist, is effective in treating major depression, studies have not addressed the safety of repeated ketamine ...
Psychedelic Therapist Sexual Misconduct and Other Adverse Experiences Among a Sample of Naturalistic Psychedelic Users.
Psychedelic medicine (New Rochelle, N.Y.) – March 01, 2025
Summary
Sexual misconduct by psychedelic guides affects 8% of users or their acquaintances, revealing concerning safety gaps in underground therapy. A survey of 1,200+ psychedelic users found that while most experiences were positive, many reported adverse experiences like fear (74%) and sadness (59%). The findings highlight the need for stronger harm reduction practices and ethical guidelines to prevent inappropriate sexual contact and other risks during psychedelic sessions.
Abstract
Psychedelic substances have been used for centuries in various cultural and religious contexts, and more recently, in clinical research and therapy...
The ketamine chameleon: history, pharmacology, and the contested value of experience.
Expert review of clinical pharmacology – March 01, 2025
Summary
Ketamine's remarkable versatility in medicine spans from battlefield anesthesia to breakthrough depression treatments. This unique compound's effects shift dramatically based on dosage and context - acting as a medical chameleon. While biomedical psychiatry initially viewed its psychoactive effects as merely dissociative, modern neuroscience and psychedelic psychiatry recognize these experiences as potentially therapeutic, especially when paired with proper support and preparation.
Abstract
Since its synthesis in 1962, ketamine has been widely used in diverse medical contexts, from anesthesia to treatment-resistant depression. However,...
Examining the pharmacokinetic and pharmacodynamic interaction of N,N-dimethyltryptamine and harmine in healthy volunteers: Α factorial dose-escalation study.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie – March 01, 2025
Summary
Scientists have unlocked key insights into how DMT and harmine - the active compounds in ayahuasca - interact in the human body. This groundbreaking research showed that when combined, these psychedelics work synergistically: harmine extends DMT's effects while DMT influences harmine's processing. The safe, controlled delivery method produced consistent 4-5 hour experiences, suggesting promising therapeutic potential.
Abstract
Ayahuasca, a traditional psychoactive Amazonian brew, usually contains N,N-dimethyltryptamine (DMT) and β-carboline (harmine, harmaline, tetrahydro...
The diverse effects of ketamine, jack-of-all-trades: a narrative review.
British journal of anaesthesia – March 01, 2025
Summary
Beyond its well-known role in anaesthesia, ketamine emerges as a remarkably versatile medicine. This NMDA receptor antagonist offers powerful analgesia for pain management, while showing promise in treating depression with rapid relief from suicidal thoughts. Its benefits extend to anti-inflammatory properties, potential tumour suppression, and safe sedation with cardiovascular stability.
Abstract
Ketamine, an N-methyl-D-aspartic acid receptor antagonist that was first discovered in 1962, has become established in anaesthesia providing dose-d...
Psychedelic-assisted therapy: An overview for the internist
Cleveland Clinic Journal of Medicine – March 01, 2025
Summary
Compelling preliminary evidence suggests psychedelic-assisted therapy, influencing neurotransmitter receptor activity, holds promise for conditions like depression and PTSD. These Psychedelics and Drug Studies, involving compounds like MDMA and psilocybin, have earned breakthrough therapy designations. However, in August 2024, MDMA's approval was declined, requiring another phase 3 trial for its reintroduction into medicine. This rigorous process highlights the careful evaluation. Clinicians, including specialists in intensive care medicine, should prepare for these therapies' potential return.
Abstract
Preliminary evidence suggests that psychedelic-assisted therapy-the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymetham...
A Phase II Study About Efficacy and Safety of the Continuous IntraVenous Infusion of Ketamine as Adjuvant to Opioids in Terminally Ill Cancer Patients With Refractory Cancer Pain (CIVIK Trial).
The American journal of hospice & palliative care – March 01, 2025
Summary
New hope for terminally ill cancer patients suffering from stubborn pain: continuous ketamine infusion shows promising results when traditional pain medications fall short. In this breakthrough approach, doctors administered carefully controlled ketamine doses alongside opioids to help patients achieve better pain control. Half of the participants experienced significant relief, with 40% achieving their personal pain goals. This innovative treatment offers a valuable option for managing severe cancer pain in palliative care settings.
Abstract
Ketamine has been used to control refractory cancer pain as an adjuvant to opioids. We conducted a prospective phase II study to investigate the ef...
Emerging medications and pharmacological treatment approaches for substance use disorders.
Pharmacology, biochemistry, and behavior – March 01, 2025
Summary
No Summary
Abstract
Medications to treat substance use disorders (SUDs) remain suboptimal or, in the case of stimulants and cannabis, non-existent. Many factors have c...
Elucidating the Phase I metabolism of psilocin in vitro.
Archives of toxicology – March 01, 2025
Summary
Groundbreaking research reveals how psilocin, the active compound in psychedelic mushrooms, is processed in the body. Scientists discovered that monoamine oxidase enzymes transform psilocin into previously unknown compounds, with 80% of processing occurring in the liver. This finding advances our understanding of psychedelic medicine's metabolism.
Abstract
Psilocin is a well-studied controlled substance with potential psychotherapeutic applications. However, research gaps remain regarding its metaboli...
The Antidepressant Effects of Vaporized N,N-Dimethyltryptamine: An Open-Label Pilot Trial in Treatment-Resistant Depression.
Psychedelic medicine (New Rochelle, N.Y.) – March 01, 2025
Summary
A groundbreaking trial found that vaporized DMT, a natural psychedelic compound, rapidly improved symptoms in people with treatment-resistant depression. Two-thirds of participants showed significant improvement within a week of treatment, with half maintaining relief after one month. The fast-acting, non-invasive nature of DMT therapy could offer new hope for those who haven't responded to conventional treatments.
Abstract
N,N-Dimethyltryptamine (DMT), a naturally occurring psychedelic tryptamine contained in the indigenous ayahuasca brew, has shown antidepressant eff...
Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA.
Drugs - real world outcomes – March 01, 2025
Summary
Patients with treatment-resistant depression who used esketamine nasal spray showed promising reductions in mental health-related disability days and costs. Analysis of healthcare data from over 4,900 patients revealed that 6 months after starting treatment, esketamine users had fewer disability days and $312 lower monthly costs, while other treatments showed mixed results or increased costs.
Abstract
Treatment-resistant depression (TRD) is related to disproportionate unemployment and productivity burden in the USA. The current study describes re...
Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?
The American journal of psychiatry – March 01, 2025
Summary
Ketamine's rapid antidepressant effects may come from an unexpected source: its interaction with both brain opioid and NMDA receptors. While traditionally viewed as just an NMDA blocker, new evidence suggests ketamine's remarkable ability to lift severe depression stems from this dual-action mechanism. This synergistic effect explains why ketamine and esketamine work differently from conventional antidepressants, offering hope for treatment-resistant patients through innovative psychopharmacology approaches.
Abstract
Ketamine is a racemic compound and medication comprised of (S)-ketamine and (R)-ketamine enantiomers and its metabolites. It has been used for deca...
Health Care Resource Use and Medical Costs Among Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine Nasal Spray or Traditional Treatments in the United States.
Clinical therapeutics – March 01, 2025
Summary
Patients with severe depression and suicidal thoughts saw a 58% reduction in acute care visits after starting esketamine nasal spray treatment. This groundbreaking analysis compared health care costs and hospital usage among different depression treatments. Esketamine patients had lower medical expenses ($1,869/month) than those receiving electroconvulsive therapy ($4,624/month), while showing stronger improvements in reducing hospital stays and emergency visits.
Abstract
Major depressive disorder with acute suicidal ideation or behavior (MDSI) is a substantial humanistic, economic, and clinical burden on patients. D...
Successful Natalizumab Treatment of Two Female Individuals With Susac Syndrome.
European journal of neurology – March 01, 2025
Summary
A breakthrough in treating Susac syndrome shows promise for patients with this rare neuroinflammatory condition. Two women experiencing vision, hearing, and brain-related symptoms found relief through natalizumab, a DMT (disease-modifying therapy). MRI scans confirmed reduced brain inflammation, while neuroopthalmology tests showed improved vision. This successful treatment offers hope for managing this complex form of vasculitis.
Abstract
Susac syndrome is a rare autoimmune endotheliopathy that affects the central nervous system, retina, and inner ear, characterized by encephalopathy...
Clinical analysis of dexmedetomidine-esketamine combined with intranasal administration before laparoscopic high ligation of hernia sac in infants and young children.
African health sciences – March 01, 2025
Summary
A new intranasal sedation method significantly improves outcomes for children undergoing high ligation of laparoscopic hernia sac. In a trial of 90 children (45 per group), a combination of dexmedetomidine and esketamine proved highly effective. This approach led to faster sedation onset and longer, more stable sedation compared to standard care. Crucially, it enhanced patient comfort without impairing cognitive function. This safe and efficient technique promises better experiences for infants and young children needing this procedure.
Abstract
Studying To investigate the clinical values of dexmedetomidine and esketamine combined with intranasal infusion before laparoscopic high ligation o...
Adverse Events Should Not Be Surprising in Psychedelic Research.
Psychedelic medicine (New Rochelle, N.Y.) – March 01, 2025
Summary
As psychedelics gain momentum in mental health treatment, balanced science communication is crucial. While these compounds show promise, adverse events in clinical trials range from mild anxiety to rare but serious psychological reactions. Medical professionals are working to better understand and communicate both benefits and risks, ensuring patients can make informed decisions. Responsible use requires careful screening and monitoring.
Abstract
Research has demonstrated both risks and benefits to using psychedelics as a therapeutic intervention for a variety of mental health conditions. In...
Therapeutic Potential of Psychedelics for Treating Anosmia: An Investigation of Online Accounts
Journal of Psychoactive Drugs – March 01, 2025
Summary
Remarkably, 86.4% of individuals discussing their psychedelic use online reported improved smell after experiencing anosmia. Analyzing 125 posts, a significant 50.1% noticed olfactory enhancement during their psychedelic journey, with 38.8% experiencing benefits lasting over a day. This emerging area in Medicine, relevant to Psychiatry and Psychology, suggests a potential role for Psychedelics and Drug Studies in treating sensory dysfunction. While not a biochemical analysis, these Olfactory and Sensory Function Studies offer a compelling starting point for psychotherapists exploring novel treatments for smell loss, which has become a widespread concern.
Abstract
Olfactory dysfunction (OD) has become increasingly prevalent since the COVID-19 pandemic, yet effective treatments remain limited. In recent years,...
Clinical indicators of the suicide crisis and response to ketamine.
Journal of affective disorders – March 01, 2025
Summary
Breakthrough findings show ketamine can rapidly reduce suicidal thoughts and psychological pain in high-risk individuals. Researchers tracked 118 adults, focusing on those who recently experienced severe suicidal thoughts or attempts. The study revealed that depression, hopelessness, and traumatic stress peak during suicide crises. Importantly, targeted ketamine treatment helped alleviate these symptoms quickly.
Abstract
This analysis sought to identify potential clinical targets for the suicide crisis. Characteristics of a useful clinical target include elevation a...
The Near-Death Experience and Self-Determination Theory.
Omega – March 01, 2025
Summary
No Summary
Abstract
When people experience a near-death or life-threatening incident, they sometimes report an altered state of consciousness in which they have the pe...
Individual differences in prioritization for consciousness and the conscious detection of changes.
Consciousness and cognition – March 01, 2025
Summary
No Summary
Abstract
A recent discovery documented robust and reliable individual differences in how quickly people become aware of non-conscious visual stimuli (Sklar,...
How to Live in the Moment: The Methodology and Limitations of Evolutionary Research on Consciousness.
Cognitive science – March 01, 2025
Summary
No Summary
Abstract
There is much interest in investigating the evolution question: How did consciousness evolve? In this paper, we evaluate the role that evolutionary...
A systematic review of participant diversity in psychedelic-assisted psychotherapy trials.
Psychiatry research – March 01, 2025
Summary
Despite promising breakthroughs in psychedelic therapy, clinical trials show concerning gaps in participant diversity. Analysis of 21 trials using MDMA and psilocybin revealed that Black participants made up only 2.2% of subjects, while Hispanic representation was just 7.2%. MDMA studies showed better diversity than psilocybin research. While gender was consistently tracked, other key demographics like sexual orientation and gender identity were rarely monitored. This systematic review highlights opportunities to make psychedelic therapy research more inclusive.
Abstract
A lack of diverse and representative participant samples in mental health intervention research perpetuates mental health disparities. This issue h...
Ketamine administration during adolescence impairs synaptic integration and inhibitory synaptic transmission in the adult dentate gyrus.
Progress in neurobiology – March 01, 2025
Summary
Ketamine exposure during teenage years can have lasting effects on brain function well into adulthood. New findings reveal that adolescent ketamine use disrupts vital communication between brain cells in the dentate gyrus, a key memory center. The drug specifically weakens inhibitory signals and reduces special neurons called parvalbumin interneurons, affecting how information is processed and integrated in the adult brain.
Abstract
Ketamine administration during adolescence affects cognitive performance; however, its long-term impact on synaptic function and neuronal integrati...
[Mechanisms of action of antidepressive pharmacotherapy: brain and mind-body and environment].
Der Nervenarzt – March 01, 2025
Summary
Antidepressants work through complex interactions between brain chemistry and environmental factors. Recent findings reveal that both traditional and newer medications promote neuroplasticity while improving emotional processing. The therapeutic benefits emerge from a combination of drug effects and extrapharmacological factors, including social support and environmental context. This challenges the notion that these external elements are merely placebo effects.
Abstract
Novel antidepressive substances are challenging the explanations for the mechanisms of action of traditional psychopharmacology. What could be the ...
Demographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: A systematic review.
Psychiatry research – March 01, 2025
Summary
Breakthrough treatments ketamine and esketamine show promise in treating major depressive disorder, helping patients who haven't responded to traditional therapies. A comprehensive analysis of 44 studies reveals that certain traits—including sleep problems, memory function, and metabolic health—may influence treatment success. While patient characteristics like age and gender don't significantly impact outcomes, those with specific symptoms like anhedonia may respond particularly well.
Abstract
Accumulating evidence supports the efficacy of (es)ketamine in the treatment of major depressive disorder (MDD), particularly treatment-resistant d...
The paradox of the self-studying brain.
Physics of life reviews – March 01, 2025
Summary
No Summary
Abstract
The paradox of a brain trying to study itself presents a conundrum, raising questions about self-reference, consciousness, psychiatric disorders, a...
Prevalence of new psychoactive substances and drugs of abuse in the hair of individuals diagnosed with substance use disorder: Polydrug and emerging pattern of consumption.
Journal of forensic sciences – March 01, 2025
Summary
Hair analysis reveals striking patterns in drug use: 96% of patients with substance use disorder tested positive for at least one substance, with two-thirds using multiple drugs. While traditional drugs dominated, new psychoactive substances emerged particularly among younger users. Ketamine appeared in 8% of cases, often alongside cocaine, while fentanyl was found in 3.4% of samples.
Abstract
People diagnosed with substance use disorder (SUD) might represent a high-risk subpopulation for New Psychoactive Drugs (NPS) consumption, and hair...
Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report.
Journal of Parkinson's disease – March 01, 2025
Summary
A groundbreaking case shows how psilocybin-assisted therapy helped a woman with Parkinson's disease transform her outlook. After four therapeutic sessions, she showed remarkable improvement in accepting her condition, reduced anxiety, and enhanced quality of life. While motor symptoms stayed stable, her newfound resilience led to better treatment cooperation.
Abstract
BackgroundPsychedelic assisted psychotherapy (PAP) can improve treatment-resistant depression. Its usefulness in Parkinson's disease (PD) is unknow...
Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.
Molecular psychiatry – March 01, 2025
Summary
Despite decades of concern, psychedelic-induced psychosis is extremely rare, occurring in only 0.002% of general population cases. Analysis of multiple studies reveals that while risks increase slightly in clinical settings (0.2-0.6%), psychedelics appear safer than previously thought. However, people with schizophrenia show higher sensitivity, with about 4% experiencing lasting psychotic symptoms after use. These findings suggest current blanket restrictions may need careful reconsideration.
Abstract
Persons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis. Howe...